other material
confidence high
sentiment neutral
materiality 0.65
Spyre Therapeutics prices $200M public offering of 7.275M shares at $27.50
Spyre Therapeutics, Inc.
- Offering includes 7,275,000 shares of common stock at $27.50; underwriters have 30-day option for 1,091,250 additional shares.
- Gross proceeds expected to be approximately $200M before expenses; net proceeds plus existing cash expected to fund operations into H2 2028.
- Underwriters: Jefferies, Goldman Sachs, Evercore, Guggenheim; closing expected Nov 20, 2024.
- Offered pursuant to Form S-3 shelf registration; prospectus supplement filed Nov 19, 2024.